<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-34GBY615</identifier><date>2009</date><creator>Ocvirk, Janja</creator><relation>documents/doc/3/URN_NBN_SI_doc-34GBY615_001.pdf</relation><relation>documents/doc/3/URN_NBN_SI_doc-34GBY615_001.txt</relation><format format_type="volume">13</format><format format_type="issue">2</format><format format_type="type">article</format><format format_type="extent">str. 127-129, 153</format><identifier identifier_type="ISSN">1408-1741</identifier><identifier identifier_type="COBISSID">855419</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-34GBY615</identifier><language>slv</language><publisher>Onkološki inštitut Ljubljana</publisher><source>Onkologija (Ljubljana)</source><rights>BY</rights><subject language_type_id="eng">Angiogenesis inhibitors</subject><subject language_type_id="slv">Angiogenezni inhibitorji</subject><subject language_type_id="eng">Antibodies, monoclonal</subject><subject language_type_id="eng">Brain neoplasms</subject><subject language_type_id="slv">Gliom</subject><subject language_type_id="slv">Glioma</subject><subject language_type_id="slv">Možgani, novotvorbe</subject><subject language_type_id="eng">Neovascularization, pathologic</subject><subject language_type_id="slv">Neovaskularizacija, patološka</subject><subject language_type_id="slv">Protitelesa, monoklonska</subject><title>Zaviralci angiogeneze v zdravljenju možganskih tumorjev</title></Record>